Study of RP3 in Combination With Nivolumab and Other Therapy in Patients With Locoregionally Advanced or Recurrent SCCHN

Charite University Hospital of Berlin, Comprehensive Cancer Center, Berlin

University General Hospital Attikon, Chaïdári

Assistance Publique Hopitaux De Marseille, Marseille

University of Pittsburgh Medical Center, UPMC, Pittsburgh

Jefferson Health Abington Asplunhd Cancer Pavillion, Willow Grove

Thomas Jefferson University City Center and Abington, Philadelphia

Centre Georges Francois Leclerc, Department of Oncology, Dijon

La Paz Univeristy Hospital, Universidad Autonoma de Madrid, Madrid

Hospital Universitario HM Sanchinarro, Madrid

CHU Nimes, Instiut de Cancerologie du Gard, Medical Oncology, Nîmes

Clinica Universitaria de Navarra, Pamplona

Sarah Cannon Research Institute, Nashville

Cleveland Clinic, Cleveland

University of Cincinnati Medical Center, Cincinnati

Fundacion Instituto Valenciano de Oncologia, Valencia

University of Iowa Hospitals and Clinics, Iowa City

Medical College of Wisconsin, Milwaukee

Agios Lukas Hospital, Thessaloniki

Centre Leon Berard, Lyon

LMU Klinikum, Medizinische Klinik und Poliklinikum III, Munich

Universitatsklinikum Ulm, Ulm

USC Norris Comprehensive Cancer Center, Los Angeles

UCLA Medicine Division of Hematology-Oncology, Los Angeles

University of California San Diego, UCSD, La Jolla

Institut Gustave Roussy Paris, Villejuif

University of Washington / Fred Hutchinson Cancer Center, Seattle

University Hospital Olomouc, Olomouc

FN Kralovske Vinohrady, Prague

Fakultni Thomayerova Nemocnice, Prague

Universitatsklinik Jena Klinik und Poliklinik fur Hals-, Nasen - und Ohrenheilkunde, Jena

University Hospital Leipzig Clinic and Polyclinic for otorhinolaryngology, Leipzig

Szpital Specjalistyczny im Ludwika Rydygiera w Krakowie sp z oo, Department of Clinical Oncology, Krakow

Vall d'Hebron University Hospital, Vall d' Hebron Institute of Oncology (VHIO), Barcelona

The Royal Marsden NHS Foundation Trust, London